Delivery Order SPE2DB22D2007-SPE2DB25FJ2AE

Award Date 6/4/25
Potential Completion Date 6/5/25
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,793.00, is for the delivery of FERUMOXYTOL 510 MG/17 ML VIAL 17ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 24, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of FERUMOXYTOL 510 MG/17 ML VIAL 17ML, a pharmaceutical product, with a ceiling value of $3,628.57 and a period of performance through June 12, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of FERUMOXYTOL 510 MG/17 ML VIAL 17ML. The delivery order, valued at $1,675.80, is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of FERUMOXYTOL 510 MG/17 ML VIAL 17ML. The contract is a Delivery Order with a Firm Fixed Price pricing type, has a ceiling value of $1,264.40, and an ultimate completion date of March 17, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp is the prime contractor for this award, which appears to be a part of a larger Indefinite Delivery...
This federal contract award, identified as SPE2DB20D3103|SPE2DB25FM1G7, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The award is for the delivery of FERUMOXYTOL 510 MG/17 ML VIAL 17ML, a pharmaceutical product, with a ceiling value of $25,220.94 and an ultimate completion date of December 27, 2024. The contract is a Delivery Order, with a Firm Fixed Price pricing type. It is not associated with any set-aside requirements....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,052.43 Firm Fixed Price Delivery Order Contract is for the supply of FERUMOXYTOL 510 MG/17 ML VIAL 17ML, which is a medical commodity used for healthcare. The contract is not designated as a set-aside and serves as a delivery order under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the...
This is a delivery order awarded to Amerisourcebergen Drug Corp's Corporate Office division by the Defense Logistics Agency (DLA), a defense agency, for the supply of FERUMOXYTOL 510 MG/17 ML VIAL 17ML. The $1,290.72 firm fixed price contract has a completion date of June 3, 2024. Amerisourcebergen is a major pharmaceutical distribution company that holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceuticals and...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 510 mg/17 ml vials of the pharmaceutical drug ferumoxytol, valued at $6,484.80. The contract has an ultimate completion date of April 9, 2025 and is a firm fixed price delivery order. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ferumoxytol 510 mg/17 ml vials. The total ceiling value of the order is $11,582.66, with a firm fixed-price contract type and an ultimate completion date of May 9, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This federal contract award is for the delivery of Ferumoxytol 510 mg/17 ml vial, awarded to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA), a defense agency. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $21,108.26 and a completion date of June 26, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that holds a significant Indefinite Delivery...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FJ2AE
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of FERUMOXYTOL 510 MG/17 ML VIAL 17ML, a pharmaceutical product. The contract has a ceiling value of $3,107.30 and is a Delivery Order under a Firm Fixed Price contract type. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, the prime contractor, is delivering the pharmaceutical product to the DLA, which is a defense agency. The contract has an ultimate completion date of June 5, 2025.

Generated 9/3/25, 10:04 AM